Internal Medicine Alert - January 30, 2012

Target Audience:

This activity is intended for the internist and family practitioner.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Internal Medicine Alert has been reviewed and is acceptable for up to 1 Prescribed credit by the American Academy of Family Physicians. AAFP accreditation begins 01/01/11. Term of approval is for one year from this date. Credit may be claimed for 1 year from the date of each issue.

Faculty

Editor
Stephen A. Brunton, MD
Clinical Professor
University of California, Irvine

Executive Editor
Leslie Coplin

Managing Editor
Neill Kimball

Associate Editors
Rahul Gupta, MD, MPH, FACP
Clinical Assistant Professor,
West Virginia University School of Medicine
Charleston, WV

William T. Elliott, MD, FACP
Chair, Formulary Committee
Northern California Kaiser Permanente
Asst. Clinical Professor of Medicine
University of California
San Francisco

James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Manager
Kaiser Permanente
Oakland, CA

Louis Kuritzky, MD
Clinical Assistant Professor
University of Florida
Gainesville

Authors
Stan Deresinski, MD, FACP, FIDSA
Clinical Professor of Medicine
Stanford University
Associate Chief of Infectious Diseases
Santa Clara Valley Medical Center
Editor for Infectious Disease Alert.

Alan Z. Segal, MD
Associate Professor of Clinical Neurology
Weill Cornell Medical College
New York, NY

Peer Reviewer
Gerald Roberts, MD
Assistant Clinical Professor of Medicine
Albert Einstein College of Medicine
New York, NY

Subjects:

Early Referral of the Chronic Kidney Disease Patient is Good Practice
Physician Protect Thyself (and Your Patients and Coworkers)!
Daytime Sleepiness as a Stroke and Cardiac Risk Factor
Clobazam Tablets (ONFI™) CIV
Clinical Briefs

Objectives:

describe new findings in differential diagnosis and treatment of various diseases
describe controversies, advantages, and disadvantages of those advances
describe cost-effective treatment regimens
describe the pros and cons of new screening procedures.

Financial Disclosure:

Internal Medicine Alert's editor, Stephen Brunton, MD, serves on the advisory board for Lilly, Boehringer Ingelheim, Novo Nordisk, Sunovion, and Teva; he serves on the speakers bureau of Boehringer Ingelheim, Lilly, Kowa, Novo Nordisk, and Teva. Associate editors Rahul Gupta, MD, MPH, FACP, William T. Elliott, MD, FACP, and James Chan, PharmD, PhD, author Alan Z. Segal, MD, peer reviewer Gerald Roberts, MD; executive editor Leslie Coplin; and managing editor Neill Kimball report no financial relationships relevant to this field of study. Author Stan Deresinski, MD, FACP, FIDSA does research for the National Institutes of Health, and is an advisory board member and consultant for Merck. Associate editor Louis Kuritzky, MD is an advisor for Endo, Kowa, Pricara, and Takeda.